Ouro makes debut with $120m for autoimmune disease TCEs
Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.
Algorithm spots common sleep disorder linked to dementia
An AI algorithm can help detect REM sleep behaviour disorder, which affects millions of people and is a warning signal for neurological diseases.
CRISPR biotech Intellia cuts staff as it eyes 2027 launch
Eyeing a first commercial launch in 2027, Intellia is re-prioritising by cutting 27% of its workforce and shelving a lung disease candidate.
World's largest proteomics trial launched by UK Biobank
A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today.
EU pharma calls for speedy shift to digital package inserts
Pharma groups have called for EU adoption of electronic product information (ePI) to take place within four years in a new position paper.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
hubXchange returns with its latest series of roundtables!
hubXchange invites you to participate in its highly-anticipated San Diego Series 2025, a series of focused, high-level roundtable events designed to address key challenges and innovations across th
Advance Best-In-Class Treatment Across CNS, Emergency Use Tr...
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
7th Treg-Directed Therapies Summit
Unravelling Treg Biology, Pioneering Best-in-Class Approaches & Demonstrating Clinical Efficacy to Advance Validated Therapeutic Options in Autoimmunity, Inflammation & Beyond
Welcome to the Bacteriophage Therapy Summit!
Combating Antibiotic Resistance with Effective & Sustainable Phage-Based Therapies
Biotech Showcase marking 17 years of innovation and opportun...
Biotech Showcase is a cornerstone of the life science industry, with a 17-year history of connecting private and micro- to mid-cap biotech companies with top-tier investors and biopharmaceu